Metabolism and Pharmacokinetics of [14C] BIBW 2992 MA2 After Administration of Single Doses of 15 mg [14C] BIBW 2992 MA2 Oral Solution in Healthy Male Volunteers

Trial Profile

Metabolism and Pharmacokinetics of [14C] BIBW 2992 MA2 After Administration of Single Doses of 15 mg [14C] BIBW 2992 MA2 Oral Solution in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Afatinib (Primary)
  • Indications Breast cancer; Colorectal cancer; Glioblastoma; Glioma; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 30 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top